

Data Sharing Statement

Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	—
Additional information about data	—
How or where can the data be obtained?	Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.
When will data availability begin?	April 29, 2020
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	—
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on October 14, 2020, at NEJM.org.